South Ko­re­an bio­phar­ma con­tract man­u­fac­tur­er Cell­tri­on is con­sid­er­ing ac­quir­ing US man­u­fac­tur­ing sites to mit­i­gate Pres­i­dent Don­ald Trump’s po ...

Two biotech com­pa­nies failed to re­verse or­ders bar­ring them from sell­ing biosim­i­lars of Re­gen­eron’s eye dis­ease drug Eylea in rul­ings from a fed­er­al ap­peals court … ...

Genen­tech is the lat­est drug­mak­er to sue the fed­er­al gov­ern­ment over STD clin­ics it says are wrong­ful­ly re­ceiv­ing dis­counts through the fed­er­al 340B pro­gram. … ...

Ver­tex Phar­ma­ceu­ti­cals and the Na­tion­al Health Ser­vice in Eng­land have reached a pay­ment deal mak­ing the gene-edit­ed ther­a­py Cas­gevy avail­able to cer­tain peo­ple ...

Robert F. Kennedy Jr.’s chances of be­com­ing HHS chief like­ly hinge on one of his more con­tro­ver­sial stances: that vac­cines con­tribute to the de­vel­op­ment of … ...

The world’s biggest al­ter­na­tive as­set man­ag­er is fur­ther ce­ment­ing it­self in the life sci­ences in­dus­try with an­oth­er fund ded­i­cat­ed to drug de­vel­op­ment.

The loss of Hu­mi­ra ex­clu­siv­i­ty was long ex­pect­ed to be a blow to Ab­b­Vie’s im­munol­o­gy dom­i­nance, but the Skyrizi-Rin­voq tan­dem keeps out­pac­ing ex­pec­ta ...

The tele­health start­up Hims & Hers comes out swing­ing against phar­ma­ceu­ti­cal com­pa­nies in a provoca­tive new ad slat­ed to air dur­ing the Su­per Bowl. … ...

As­traZeneca has can­celed its plans to ex­pand its vac­cine man­u­fac­tur­ing site in Speke, UK, af­ter the new UK gov­ern­ment trimmed fund­ing for the project, a … ...

Ger­man CD­MO Rentschler Bio­phar­ma is clos­ing down its cell and gene ther­a­py op­er­a­tions and shut­ter­ing a fa­cil­i­ty in the UK, which could af­fect up to … ...

Sev­er­al months in­to a mul­ti­year quest to “rig­or­ous­ly pri­or­i­tize” its pipeline, Take­da is cut­ting a hand­ful of pro­grams.

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.